mRNA |
Crizotinib |
GDSC1000 |
pan-cancer |
AAC |
0.043 |
0.4 |
mRNA |
selumetinib:GDC-0941 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.028 |
0.4 |
mRNA |
SNX-2112:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.026 |
0.4 |
mRNA |
GDC-0941 |
CTRPv2 |
pan-cancer |
AAC |
-0.029 |
0.4 |
mRNA |
YL54 |
CTRPv2 |
pan-cancer |
AAC |
-0.031 |
0.4 |
mRNA |
FR-180204 |
GDSC1000 |
pan-cancer |
AAC |
-0.03 |
0.4 |
mRNA |
quizartinib |
CTRPv2 |
pan-cancer |
AAC |
-0.029 |
0.4 |
mRNA |
Sunitinib |
GDSC1000 |
pan-cancer |
AAC |
-0.041 |
0.4 |
mRNA |
MI-1 |
CTRPv2 |
pan-cancer |
AAC |
0.031 |
0.4 |
mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.028 |
0.4 |